Toxicity of intensive first-line treatment for adult Burkitt lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective, single-center observational analysis of adults with Burkitt lymphoma treated at Strasbourg University Hospitals. It aims to characterize short- and long-term treatment-related toxicities, overall survival at five years, and progression-free survival at 24 months. Secondary goals include examining how treatment delays and dose reductions relate to toxicity, and how disease location at diagnosis influences outcomes. Eligibility includes adults diagnosed or managed for Burkitt lymphoma between 2009 and 2025, with consent for reuse of data unless objected. The study uses existing medical records to summarize historical treatment patterns and outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 years or older.
* Patients diagnosed with Burkitt lymphoma at Strasbourg University Hospitals between January 1, 2009, and December 31, 2025, and/or managed by the Hematology Department of Strasbourg University Hospitals or ICANS for Burkitt lymphoma during this period.
* No written objection documented in the medical record to the reuse of personal data for scientific research.

Exclusion Criteria:

* Patients who have objected to the reuse of their personal data for scientific research.
* Patients diagnosed with another B-cell non-Hodgkin lymphoma other than Burkitt lymphoma.
* Patients for whom accessible data are unavailable.
* Individuals under legal protection (sauvegarde de justice).
* Individuals under guardianship or curatorship (tutelle or curatelle).

Where it's running

• Service d'Hématologie et d'Oncologie - CHU de Strasbourg, France
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Marie-Pierre LEDOUX, MD
• Email: mariepierre.ledoux@chru-strasbourg.fr
• Phone: 33 3 68 76 74 07

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Telenursing to detect and manage side effects from CDK4/6 inhibitors in breast cancer

  This project tests whether scheduled phone or video contacts from trained nurses, added to usual care, help people with breast cancer taking CDK4/6 inhibitors notice and manage side effects earlier and stay on treatment.

  Recruiting Azienda Sanitaria Locale di Asti · Asti, ASTI · NCT07524829

• Gut microbiome in gynecologic cancer patients with pelvic toxicity

  This study looks at whether gut bacteria profiles relate to pelvic toxicity after cancer treatment and how rectal ozone therapy might affect the gut microbiome and symptoms in women with gynecologic tumors.

  Recruiting at 2 sites Hospital Universitario de Gran Canaria Doctor Negrín · Las Palmas de Gran Canaria, Las Palmas and 1 other locations · NCT07259681

• Impact of muscle loss on chemotherapy side effects in cancer patients

  This study is testing how muscle loss affects the side effects of chemotherapy in cancer patients to see if it makes treatment harder to handle.

  Recruiting Centre Hospitalier Metropole Savoie · Chambéry · NCT06274268

• Effects of cancer treatments on fertility

  This study looks at how cancer treatments like chemotherapy and radiation affect fertility in both men and women by checking hormone and sperm levels before and after treatment.

  Recruiting Universitätsklinik fur Frauenheilkunde, Inselspital Bern · Bern · NCT05885048

• Using Metformin with FOLFIRI chemotherapy for metastatic colorectal cancer

  This study is testing if adding Metformin to FOLFIRI chemotherapy can help people with metastatic colorectal cancer live longer and feel better.

  Recruiting Phase 2 Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung City · NCT06826092

• Using olanzapine to improve survival in patients with advanced gastrointestinal and lung cancer

  This study is testing if adding the medication olanzapine to regular cancer treatment and nutritional advice can help people with advanced gastrointestinal and lung cancers live longer and feel better.

  Recruiting Phase 3 Qinghai Red Cross Hospital · Xining, Qinghai · NCT06338683

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.